Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Ezekowitz

Showing results (91-100 of 187) with videos related to

Pageof 19
Sort By:
Circulation|March 1, 2012
Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudyZiad Hijazi, Jonas Oldgren, Ulrika Andersson, et al.
The American Journal of Cardiology|October 24, 2007
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)Michael D Ezekowitz, Paul A Reilly, Gerhard Nehmiz, et al.
European Heart Journal|September 28, 2020
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillationLars Wallentin, Johan Lindbäck, Niclas Eriksson, et al.
Circulation|December 11, 2013
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysisZiad Hijazi, Stefan H Hohnloser, Jonas Oldgren, et al.
Circulation|November 26, 2014
Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis"Ziad Hijazi, Stefan H Hohnloser, Jonas Oldgren, et al.
Circulation|October 3, 2012
Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trialHarriette G C Van Spall, Lars Wallentin, Salim Yusuf, et al.
European Heart Journal|April 17, 2018
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trialMichael D Ezekowitz, Charles V Pollack, Jonathan L Halperin, et al.
Annals of Internal Medicine|November 16, 2011
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trialJonas Oldgren, Marco Alings, Harald Darius, et al.
Circulation|December 15, 2010
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillationMichael D Ezekowitz, Lars Wallentin, Stuart J Connolly, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 19, 2017
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) studyPaolo Verdecchia, Gianpaolo Reboldi, Fabio Angeli, et al.
Pageof 19

Showing results (91-100 of 187) with videos related to

Sort By:
Pageof 19
Circulation|March 1, 2012
Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudyZiad Hijazi, Jonas Oldgren, Ulrika Andersson, et al.
The American Journal of Cardiology|October 24, 2007
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)Michael D Ezekowitz, Paul A Reilly, Gerhard Nehmiz, et al.
European Heart Journal|September 28, 2020
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillationLars Wallentin, Johan Lindbäck, Niclas Eriksson, et al.
Circulation|December 11, 2013
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysisZiad Hijazi, Stefan H Hohnloser, Jonas Oldgren, et al.
Circulation|November 26, 2014
Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis"Ziad Hijazi, Stefan H Hohnloser, Jonas Oldgren, et al.
Circulation|October 3, 2012
Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trialHarriette G C Van Spall, Lars Wallentin, Salim Yusuf, et al.
European Heart Journal|April 17, 2018
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trialMichael D Ezekowitz, Charles V Pollack, Jonathan L Halperin, et al.
Annals of Internal Medicine|November 16, 2011
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trialJonas Oldgren, Marco Alings, Harald Darius, et al.
Circulation|December 15, 2010
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillationMichael D Ezekowitz, Lars Wallentin, Stuart J Connolly, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 19, 2017
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) studyPaolo Verdecchia, Gianpaolo Reboldi, Fabio Angeli, et al.
Pageof 19